Syneos Health (SYNH)
(Delayed Data from NSDQ)
$37.58 USD
-0.35 (-0.92%)
Updated Feb 6, 2023 04:00 PM ET
After-Market: $37.59 +0.01 (0.03%) 7:58 PM ET
5-Strong Sell of 5 5
A Value D Growth D Momentum C VGM
Price, Consensus and EPS Surprise
SYNH 37.58 -0.35(-0.92%)
Will SYNH be a Portfolio Killer in February?
Zacks Investment Research is releasing its prediction for SYNH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SYNH
Syneos Health (SYNH) Signs New Partnership With Cryoport
Implied Volatility Surging for Syneos Health (SYNH) Stock Options
SYNH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Syneos Health (SYNH) to Launch Serplulimab With New Pact
Syneos Health (SYNH) Hurt by Low Reimbursable Expense, FX Issue
Syneos Health (SYNH) to Enhance Clinical Trials With New Pact
Other News for SYNH
ClearBridge Mid Cap Growth Strategy Q4 2022 Portfolio Manager Commentary
ClearBridge Small Cap Growth Strategy Q4 2022 Portfolio Manager Commentary
ClearBridge Mid Cap Strategy Q4 2022 Portfolio Manager Commentary
ClearBridge Small Cap Value Strategy Q4 2022 Portfolio Manager Commentary
Cryoport Announces New Strategic Partnership with Syneos Health to Advance Cell & Gene Therapies